30 December 2024 Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues.
Shares of US drug developer Aerovate Therapeutics plummeted 93% yesterday and were down a further 6.7% at $1.54 pre-market, after it revealed it would scrap a late-stage development of its lead investigational candidate. 18 June 2024
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Johnson & Johnson continues to be the world's most valuable and strongest pharmaceutical brand, according to a new report by Brand Finance. 18 June 2024
Takeda, Japan’s largest drugmaker, today announced mixed top-line data from its SKYLINE and SKYWAY Phase III trials outcomes for its drug soticlestat. 17 June 2024
Japanese drugmaker Mitsubishi Tanabe Pharma (MTPC) has entered into an agreement with Paris, France-based Ethypharm for the transfer of the business of the selective antithrombin agent, argatroban monohydrate in Europe. 17 June 2024
"There is a need for good conditions for entrepreneurs in Denmark. It is an important piece if we hope to maintain and expand our global position, not least within life science and biotech," says Ida Sofie Jensen, chief executive of the Danish Pharmaceutical Industry Association, Lif. 17 June 2024
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Augtyro (repotrectinib), from Bristol Myers Squibb), for a new indication. 14 June 2024
Bladder cancer specialist UroGen Pharma saw its shares close up nearly 38% at $17.50 yesterday, after it shared positive trial results on its lead pipeline candidate UGN-102, an innovative formulation of mitomycin. 14 June 2024
As the UK heads for a general election next month, the Association of the British Pharmaceutical Industry (ABPI) today assessed the Labour Party manifesto, having yesterday appraised the UK Conservative pledges. 13 June 2024
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Johnson & Johnson says it has “grave concern” for the availability of future innovative mental health treatments in England, following a decision by National Institute for Health and Care Excellence (NICE) to not re-appraise Spravato (esketamine nasal spray) for treatment-resistant depression in England 13 June 2024
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration to improve glycemic control in children with type-2 diabetes (T2D). 13 June 2024
Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an IPO this summer, which could come as soon as late July. 13 June 2024
The US Centers for Medicare & Medicaid Services’ (CMS) Office of the Actuary has released projections of National Health Expenditures (NHE) and health insurance enrollment for the years 2023-2032. 13 June 2024
Flagship Pioneering and its founded company ProFound Therapeutics today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. 12 June 2024
The Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), has selected Australian drugmaker CSL Ltd’s subsidiary CSL Seqirus to provide 665,000 pre-pandemic vaccine doses for 15 European Union and European Economic Area (EEA) member states as well as to the "Union Civil Protection Mechanism" (rescEU). 12 June 2024
Helsinn Group and Chugai Pharma Europe have announced the renewal of their distribution and license agreement for Akynzeo (netupitant-palonosetron) in the UK and Ireland. 12 June 2024
US Senator Bernie Sanders, chairman of the Senate Committee on Health, Education, Labor and Pensions (HELP), has announced that members will vote next week on whether to subpoena Doug Langa, senior vice president, head of North America operations and president of Novo Nordisk. 12 June 2024
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
The US Food and Drug Administration (FDA) is reopening the comment period for the Federal Register notice (FRN), “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments” due to high interest from industry. 31 December 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning urging the public to avoid purchasing weight-loss medicines without a prescription. 30 December 2024
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia disorders, from domestic drug giant Takeda Pharma 27 December 2024
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing. 27 December 2024
Akums, India’s largest contract development and manufacturing organization (CDMO), has signed a strategic agreement with an undisclosed global pharmaceutical company. 27 December 2024